Literature DB >> 23369826

Survival advantage in black versus white men with CKD: effect of estimated GFR and case mix.

Csaba P Kovesdy1, L Darryl Quarles, Evan H Lott, Jun Ling Lu, Jennie Z Ma, Miklos Z Molnar, Kamyar Kalantar-Zadeh.   

Abstract

BACKGROUND: Black dialysis patients have significantly lower mortality compared with white patients, in contradistinction to the higher mortality seen in blacks in the general population. It is unclear whether a similar paradox exists in patients with non-dialysis-dependent chronic kidney disease (CKD), and if it does, what its underlying reasons are. STUDY
DESIGN: Historical cohort. SETTING & PARTICIPANTS: 518,406 white and 52,402 black male US veterans with non-dialysis-dependent CKD stages 3-5. PREDICTOR: Black race. OUTCOMES & MEASUREMENTS: We examined overall and CKD stage-specific all-cause mortality using parametric survival models. The effect of sociodemographic characteristics, comorbid conditions, and laboratory characteristics on the observed differences was explored in multivariable models.
RESULTS: During a median follow-up of 4.7 years, 172,093 patients died (mortality rate, 71.0 [95% CI, 70.6-71.3] per 1,000 patient-years). Black race was associated with significantly lower crude mortality (HR, 0.95; 95% CI, 0.94-0.97; P < 0.001). The survival advantage was attenuated after adjustment for age (HR, 1.14; 95% CI, 1.12-1.16), but was magnified after full multivariable adjustment (HR, 0.72; 95% CI, 0.70-0.73; P < 0.001). The unadjusted survival advantage of blacks was more prominent in those with more advanced stages of CKD, but CKD stage-specific differences were attenuated by multivariable adjustment. LIMITATIONS: Exclusively male patients.
CONCLUSIONS: Black patients with CKD have lower mortality compared with white patients. The survival advantage seen in blacks is accentuated in patients with more advanced stages of CKD, which may be explained by changes in case-mix and laboratory characteristics occurring during the course of kidney disease. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.

Entities:  

Keywords:  Race; chronic kidney disease; mortality

Mesh:

Year:  2013        PMID: 23369826      PMCID: PMC3644312          DOI: 10.1053/j.ajkd.2012.12.012

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  38 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2002-08-15       Impact factor: 2.373

3.  Improving Medicare's data on race and ethnicity.

Authors:  A Marshall McBean
Journal:  Medicare Brief       Date:  2006-10

4.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

5.  Genetic basis of nondiabetic end-stage renal disease.

Authors:  Barry I Freedman; Rulan S Parekh; W H Linda Kao
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

Review 6.  Are the creatinine-based equations accurate to estimate glomerular filtration rate in African American populations?

Authors:  Pierre Delanaye; Christophe Mariat; Nicolas Maillard; Jean-Marie Krzesinski; Etienne Cavalier
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-24       Impact factor: 8.237

Review 7.  The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.

Authors:  Barry I Freedman; Jeffrey B Kopp; Carl D Langefeld; Giulio Genovese; David J Friedman; George W Nelson; Cheryl A Winkler; Donald W Bowden; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 10.121

8.  Dose of hemodialysis and survival: differences by race and sex.

Authors:  W F Owen; G M Chertow; J M Lazarus; E G Lowrie
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

9.  White/black racial differences in risk of end-stage renal disease and death.

Authors:  Andy I Choi; Rudolph A Rodriguez; Peter Bacchetti; Daniel Bertenthal; German T Hernandez; Ann M O'Hare
Journal:  Am J Med       Date:  2009-07       Impact factor: 4.965

10.  HCFA's racial and ethnic data: current accuracy and recent improvements.

Authors:  S L Arday; D R Arday; S Monroe; J Zhang
Journal:  Health Care Financ Rev       Date:  2000
View more
  21 in total

1.  Association of body mass index with outcomes in patients with CKD.

Authors:  Jun Ling Lu; Kamyar Kalantar-Zadeh; Jennie Z Ma; L Darryl Quarles; Csaba P Kovesdy
Journal:  J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 10.121

2.  Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort.

Authors:  Faraz S Ahmad; Xuan Cai; Katherine Kunkel; Ana C Ricardo; James P Lash; Dominic S Raj; Jiang He; Amanda H Anderson; Matthew J Budoff; Julie A Wright Nunes; Jason Roy; Jackson T Wright; Alan S Go; Martin G St John Sutton; John W Kusek; Tamara Isakova; Myles Wolf; Martin G Keane
Journal:  Am J Hypertens       Date:  2017-08-01       Impact factor: 2.689

3.  APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease.

Authors:  Lijun Ma; Carl D Langefeld; Mary E Comeau; Jason A Bonomo; Michael V Rocco; John M Burkart; Jasmin Divers; Nicholette D Palmer; Pamela J Hicks; Donald W Bowden; Janice P Lea; Jenna O Krisher; Margo J Clay; Barry I Freedman
Journal:  Kidney Int       Date:  2016-05-06       Impact factor: 10.612

Review 4.  Social Determinants of Racial Disparities in CKD.

Authors:  Jenna M Norton; Marva M Moxey-Mims; Paul W Eggers; Andrew S Narva; Robert A Star; Paul L Kimmel; Griffin P Rodgers
Journal:  J Am Soc Nephrol       Date:  2016-05-13       Impact factor: 10.121

Review 5.  Risk of chronic kidney disease after cancer nephrectomy.

Authors:  Lin Li; Wei Ling Lau; Connie M Rhee; Kevin Harley; Csaba P Kovesdy; John J Sim; Steve Jacobsen; Anthony Chang; Jaime Landman; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

Review 6.  Mortality Disparities in Racial/Ethnic Minority Groups in the Veterans Health Administration: An Evidence Review and Map.

Authors:  Kim Peterson; Johanna Anderson; Erin Boundy; Lauren Ferguson; Ellen McCleery; Kallie Waldrip
Journal:  Am J Public Health       Date:  2018-03       Impact factor: 9.308

7.  Racial Disparities in Nephrology Consultation and Disease Progression among Veterans with CKD: An Observational Cohort Study.

Authors:  Jonathan Suarez; Jordana B Cohen; Vishnu Potluri; Wei Yang; David E Kaplan; Marina Serper; Siddharth P Shah; Peter Philip Reese
Journal:  J Am Soc Nephrol       Date:  2018-08-17       Impact factor: 10.121

8.  Eliminating Health Disparities: What Can We Learn From the Veterans Health Administration?

Authors:  Nakela L Cook; George A Mensah
Journal:  Circulation       Date:  2015-09-18       Impact factor: 29.690

9.  Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans.

Authors:  Csaba P Kovesdy; Keith C Norris; L Ebony Boulware; Jun L Lu; Jennie Z Ma; Elani Streja; Miklos Z Molnar; Kamyar Kalantar-Zadeh
Journal:  Circulation       Date:  2015-09-18       Impact factor: 29.690

10.  Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies.

Authors:  James P Lash; Ana C Ricardo; Jason Roy; Rajat Deo; Michael Fischer; John Flack; Jiang He; Martin Keane; Claudia Lora; Akinlolu Ojo; Mahboob Rahman; Susan Steigerwalt; Kaixiang Tao; Myles Wolf; Jackson T Wright; Alan S Go
Journal:  Am J Kidney Dis       Date:  2016-05-19       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.